Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytoprotective therapies in stroke

B S Meldrum1

  • 1Department of Neurology, Institute of Psychiatry, London, UK.

Current Opinion in Neurology
|February 1, 1995
PubMed
Summary

Researchers are exploring new cytoprotective drugs to treat ischaemia (lack of blood flow). While promising in animal models, clinical trials for these neuroprotective agents are still pending, with improved trial designs focusing on early treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurotransmission in epilepsy.

Epilepsia·2012
Same author

Glutamate receptors and schizophrenia.

Journal of psychopharmacology (Oxford, England)·2011
Same author

Brain regional amino acid levels in seizure susceptible rats: Changes related to sound-induced seizures.

Neurochemistry international·2010
Same author

Actions of whole and fractionated indian cobra (naja naja) venom on skeletal muscle.

British journal of pharmacology and chemotherapy·2008
Same author

Why and when are seizures bad for the brain?

Trends in pharmacological sciences·2001
Same author

Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid.

European journal of pharmacology·2001

Area of Science:

  • Neuroscience
  • Pharmacology
  • Ischaemia Research

Background:

  • Cytoprotective strategies are crucial for mitigating ischaemic damage.
  • Animal models of focal and global ischaemia are key research tools.
  • Identifying effective pharmacological agents remains a priority.

Purpose of the Study:

  • To review current cytoprotective strategies for ischaemia.
  • To highlight pharmacological agents effective in reducing ischaemic damage.
  • To discuss challenges and improvements in clinical trial design.

Main Methods:

  • Investigation of pharmacological agents in animal models of ischaemia.
  • Analysis of mechanisms including reduced neuronal activity and ion channel modulation.
  • Evaluation of compounds targeting excitotoxic pathways (nitric oxide synthase inhibitors, free-radical scavengers).

Main Results:

  • Various compounds show differential efficacy against different types of ischaemia (reversible/permanent focal, transient).
  • Agents reducing sodium and calcium influx are effective early interventions.
  • Nitric oxide synthase inhibitors and free-radical scavengers target later excitotoxic stages.

Conclusions:

  • Despite promising preclinical data, clinical trial success for cytoprotective therapies is limited.
  • Improvements in clinical trial design, including early intervention and refined criteria, are ongoing.
  • Results from ongoing clinical trials are highly anticipated in the field of ischaemia treatment.

Related Experiment Videos